Caring for patients by making tomorrow's Biologics medicines in partnership 🤝; an inter-disciplinary translator;🚶🏻✝️; 🚵♀️; Opinions are only mine 🦋
While smart Biologics are making exciting progress🚨we shouldn’t discount the canonical/vanilla mAbs🍦. These still account for over 50% of the commercial R&D clinical pipelines 💪 and of the 16 Biologics approved by the FDA 🎉in 2024: 10 are mAbs🍦3 are bispecific🥂 https://lnkd.in/e88uen8y. This is a nice piece by Matthew Pillar on antibodies, related AI, CMC and formats: https://lnkd.in/efYd_Dfj. #innovation #precisionmedicine #pharmacology #biologics #antibodies #oncology #biotechnology #AI #CMC #BPD #scienceandtechnology #reflections
Thank you, Andrew Buchanan FRSC, really appreciate the share. We're still (and will remain) energized by the antibody builders!
Founder and Principal Consultant at Creative Antibodies
4dAn interesting topic, and worth discussing. My take is that the future belongs to complex and multi-specific, with a diminishing though not negligible share of plain mAbs. Why? Because there is a growing number of discovery efforts, and a limited number of targets, but an almost unlimited number of target combinations and/or complex therapeutic modalities (e.g. ADC, RT). With the ability to routinely make well-behaved bispecifics now coming on line, the success rate for bispecific/complex discovery does not have to be particularly high for these molecules to dominate. But when? The approvals this year and next are drugs that came out of the discovery "class of '16" or so - they do not represent what today's discovery efforts will produce in 8 years. There is always a lag. But I believe that as an ever larger number of complex antibodies enter clinical trials, enough of them will be winners to take over as the dominant class by 2032 or so.